2minutemedicine.com1h
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
The Financial Express1d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Pharmaceutical Technology3d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Investor's Business Daily on MSN3d
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.
Gas exchange and lactate threshold are valid indicators of moderate-intensity aerobic exercise, rat study finds
Researchers at University of Tsukuba identified a previously unconfirmed gas exchange threshold in rats and demonstrated that ...